Sign In
Buy SYRS
$0.0002
+0 (+0%)
At Close: Jun 03, 2026
Syros Pharmaceuticals A Buy Given Stock Price And Pipeline Potential (Rating Upgrade)
01:52am, Sunday, 15'th Jan 2023
Syros Pharmaceuticals is developing cancer therapies. Its most advanced potential therapy is tamibarotene for MDS.
Syros Pharmaceuticals, Inc. (SYRS) Q3 2022 Earnings Call Transcript
01:19pm, Monday, 14'th Nov 2022
Syros Pharmaceuticals, Inc. (NASDAQ:SYRS ) Q3 2022 Earnings Conference Call November 14, 2022 8:30 AM ET Company Participants Karen Hunady - Director-Corporate Communications & Investor Relations Nanc
Syros Pharmaceuticals, Inc. (SYRS) Reports Q3 Loss, Misses Revenue Estimates
09:47am, Monday, 14'th Nov 2022
Syros Pharmaceuticals, Inc. (SYRS) delivered earnings and revenue surprises of 38.36% and 21.65%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for t
Syros Pharmaceuticals, Inc. (SYRS) Upgraded to Buy: What Does It Mean for the Stock?
01:32pm, Friday, 23'rd Sep 2022
Syros Pharmaceuticals, Inc. (SYRS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Syros (SYRS) Up on FDA's Orphan Tag for Pancreatic Cancer Drug
02:59pm, Wednesday, 14'th Sep 2022
Syros Pharmaceuticals (SYRS) receives Orphan Drug designation from the FDA for its pipeline candidate AY-5609 being developed for treating metastatic pancreatic cancer. Stock up.
Best Penny Stocks To Buy Now That CPI Inflation Data's Out?
07:40pm, Wednesday, 10'th Aug 2022
Penny stocks to watch this week. The post Best Penny Stocks To Buy Now That CPI Inflation Data's Out?
Syros Pharmaceuticals, Inc. (SYRS) CEO Nancy Simonian on Q2 2022 Results - Earnings Call Transcript
02:29pm, Tuesday, 09'th Aug 2022
Syros Pharmaceuticals, Inc. (NASDAQ:SYRS ) Q2 2022 Earnings Conference Call August 9, 2022 8:30 AM ET Company Participants Courtney Solberg - Manager of Corporate Communications & Investor Relations N
Syros to Report Second Quarter 2022 Financial Results on Tuesday, August 9, 2022
07:30am, Tuesday, 02'nd Aug 2022
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that it will host a live conferen
TYME Technologies Shares Surge On Merger Agreement With Syros Pharma
08:16am, Tuesday, 05'th Jul 2022
Syros Pharmaceuticals Inc (NASDAQ: SYRS) has agreed to acquire TYME Technologies Inc (NASDAQ: TYME), including its pipeline assets and net cash, after accounting for wind-down and transaction expe
Syros to Present at JMP Securities Life Sciences Conference
07:30am, Wednesday, 08'th Jun 2022
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that its Chief Executive Officer,
Syros Pharmaceuticals, Inc. (SYRS) CEO Nancy Simonian on Q1 2022 Results - Earnings Call Transcript
01:21pm, Monday, 16'th May 2022
Syros Pharmaceuticals, Inc. (NASDAQ:SYRS ) Q1 2022 Earnings Conference Call May 16, 2022 8:30 AM ET Company Participants Courtney Solberg - Manager, Corporate Communications and IR Nancy Simonian - CE
Syros Pharmaceuticals, Inc. (SYRS) Reports Q1 Loss, Tops Revenue Estimates
09:47am, Monday, 16'th May 2022
Syros Pharmaceuticals, Inc. (SYRS) delivered earnings and revenue surprises of 16.67% and 20%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stoc
Syros' CDK12 Inhibitor Shows Anti Tumor Activity In Preclinical Studies
09:30am, Monday, 11'th Apr 2022
Syros Pharmaceuticals Inc (NASDAQ: SYRS) announced new preclinical data from its CDK12 inhibitor program, demonstrating robust anti-tumor activity in models of breast, lung, and ovarian cancer, inc
Syros Pharmaceuticals, Inc. (SYRS) CEO Nancy Simonian on Q4 2021 Results - Earnings Call Transcript
06:44pm, Tuesday, 15'th Mar 2022 Seeking AlphaSyros Pharmaceuticals, Inc. (SYRS) CEO Nancy Simonian on Q4 2021 Results - Earnings Call Transcript
02:44pm, Tuesday, 15'th Mar 2022
Syros Pharmaceuticals, Inc. (SYRS) CEO Nancy Simonian on Q4 2021 Results - Earnings Call Transcript
